Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity in Patients Undergoing Major Abdominal Cancer Surgeries
Description:
Intrathecal (IT) adjuvants prolong the duration of spinal anesthesia and postoperative
analgesia thereby reducing the requirement of postoperative supplemental analgesics. The
incorporation of adjuvants also lowers the overall dose of local anesthetic and hence
associated side effects. Morphine has been used widely to alleviate various types of pain and
to supplement general anesthesia. On the other hand, morphine has been reported to possess
some immunosuppressive effects. Postoperative immunity is also important in conjunction with
defence against malignant tumour. Dexmedetomidine is a highly selective α2 agonist with
analgesia, sedation, anxiolysis, and sympatholysis as its useful pharmacological actions. The
extended analgesic efficacy of IT dexmedetomidine (ITD) in the postoperative period has been
shown in a few clinical studies. In addition, current insights have identified that
dexmedetomidine has a capacity in inhibiting the overproduction of a variety of inflammatory
molecules including TNF-α, IL-1β, and IL-6 in several acute inflammatory animal models.
Condition:
Immune System Suppression
Treatment:
Morphine Sulfate
Start Date:
January 2017
Sponsor:
Assiut University
For More Information:
https://clinicaltrials.gov/show/NCT03024957